LCZ696 reduced diet-induced atherosclerotic plaque area to 23.6% compared to 33.1% with hydralazine in ApoE-deficient mice, but showed no significant difference compared to valsartan.
Does sacubitril/valsartan reduce atherosclerotic lesion progression and vascular inflammation in ApoE-/- mice compared to hydralazine or valsartan?
In a mouse model of diet-induced atherosclerosis, sacubitril/valsartan attenuated plaque progression and vascular inflammation compared to a non-RAAS inhibitor (hydralazine), but provided no additional anti-atherosclerotic benefit over valsartan alone.
Absolute Event Rate: 23.6% vs 33.1%
p-value: p=<0.05
LCZ696 reduced the progression of diet-induced atherosclerotic plaques and vascular inflammation compared with hydralazine in ApoE-/- mice, but showed no difference compared with the valsartan group. J. Med. Invest. 73 : 116-120, February, 2026.
Maeda et al. (Thu,) conducted a other in Atherosclerosis and vascular inflammation. LCZ696 (sacubitril/valsartan) vs. Hydralazine (10 mg/kg/day) or Valsartan (50 mg/kg/day) was evaluated on Atherosclerotic lesions in the aortic arch (percentage of Sudan IV-positive area) (p=<0.05). LCZ696 reduced diet-induced atherosclerotic plaque area to 23.6% compared to 33.1% with hydralazine in ApoE-deficient mice, but showed no significant difference compared to valsartan.